Read More

E2open Parent Holdings Sees Fiscal 2024 Subscription GAAP Revenue $533M-$536M; Fiscal 2024 Total GAAP Revenue $628M-$633M Vs $629.53M Est.; Fiscal Q4 2024 GAAP Subscription Revenue $131M-$134M; Fiscal 2024 Non-GAAP Gross Profit Margin 68%-70%

Financial Outlook for Fiscal Year 2024As of January 9, 2024, e2open is updating full year 2024 guidance previously provided on October 10, 2023, and providing fourth quarter 2024 guidance as follows:Fiscal 2024

ETWO

Read More

C4 Therapeutics Announces 2024 Priorities; Unaudited Cash, Cash Equivalents and Marketable Securities Totaling ~$330M As of January 5, 2024 To Advance Portfolio Of Targeted Protein Degradation Medicines; Announces Workforce Reduction Of ~30%

Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials Prioritization of CFT7455, CFT1946, Discovery Collaborations and Focused Discovery Research

CCCC

Read More

Why Is Microbiome-Based Seres Therapeutics Stock Trading Higher Today?

Seres Therapeutics Inc (NASDAQ: MCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections and to reduce the incidence of severe acute graft-versus-host disease in immunocompromised patients un

MCRB